Here you can find an archive of all the presentations that took place during the 1st Latin American Pharmacogenomics and Personalized Medicine Congress. They are arranged by date.

• Evolutionary Genetics of Alzheimer’s Disease – Allen D. Roses, MD

• Successes and Challenges in Pharmacogenomics – Lawrence J. Lesko, Ph.D., F.C.P.

• Efficacy Pharmacogenetics: Lessons from Tamoxifen – Howard L. McLeod

• Genomic Markers of Survival in Patients Treated with Cancer Chemotherapy – Federico Innocenti, MD, PhD

• Multivariate Gene Expression Profiles: An Effective Approach to Develop Clinically Useful Diagnostics – Luis Parodi, MD PhD

• Admixture in the Puerto Rican Population: Physiogenomic Analysis and Implications for Personalized Medicine – Jorge Duconge, PhD

• Genomic Diversity of Mexican Mestizo and Amerindian Groups – Irma Silva Zolezzi, PhD.

• Pharmacogenomic Implications of Genetic Admixture In Brazilians – Guilherme Suarez-Kurtz

• Genome-wide Analyses in Admixed Populations: Challenges and Opportunities – Esteban J. Parra, Ph.D.

• Population Structure and Genetic Association Studies in Admixed Populations – Dara Torgerson, Ph.D.

• High Througput Analysis of Genetic Diverstiy in ADME Related Genes in the Mexican Population: PGENI Mexico – Dr. Alfredo Hidalgo Miranda

• Scientific Advantages of Genetic Studies in Racially AdMixed Populations – Esteban González Burchard, M.D., M.P.H.

• Geography and History Shape Fine-Scale Genomic Admixture Patterns in Puerto Rico – Juan C. Martínez-Cruzado, Ph.D.

• Translational Pharmacogenomics:The FDA Experience – Mike Pacanowski, Pharm.D., M.P.H.

• Pharmacogenomics: a Case Study of International Regulatory Collaboration – Marisa Papaluca Amati

• Ways and Means in the Development of Pharmacogenomics – Federico Goodsaid, Ph.D.

• Translation of Genetic Technologies into the Clinical Space: DMET – Rick Hockett, MD

• Application of Next-Generation Sequencing to Pharmacogenomics – Alex Parker, PhD

• Delivering the Value of Personalized Medicine to Physicians, Patients and Payors – David Logan

• Pharmacogenomics for Hemoglobinopathies – George P. Patrinos

• Real World Pharmacogenomics Why, How, and When – Felix W. Frueh, PhD

• Infrastructure for Developing Pharmacogenomics: Genotype-Guided Psychotropic Management at the Institute of Living – Gualberto Ruaño, M.D., Ph.D.

• Pharmacogenetics as a Public Health Tool – Howard L. McLeod

• Pharmacogenetic Studies In Brazilians: Anticoagulants and HIV-Protease Inhibitors – Guilherme Suarez-Kurtz

• ADHD Pharmacogenetics- Mara H. Hutz

• Pharmacogenetics studies: Results and Regulatory perspectives in Cuba – Dra.DiadelisRemirez

• KRAS as a Negative Selection Pharmacogenomic Biomarker: The Path to Clinical Usefulness – Scott D. Patterson

• The International Serious Adverse Events Consortium (iSAEC) Unraveling the genetic basis of drug induced liver Injury – Sally John

• Pharmacogenetics and Thienopyridines – Sandra Close Kirkwood, PhD

• Paying for Pharmacogenomics – Felix Frueh

• Integration of Genetic Testing into Evidence-based Guidelines: the Kaiser Permanente Experience – Carlos Iribarren, MD, MPH, PhD

• Paying for Pharmacogenomics – Francisco Joglar, MD.FACP.

• MAPFRE - Edgardo J. Silva-Jiménez

• AMGEN - Emilio Rivera